Relonchem Ltd receives Marketing Authorization for Ibuprofen and Paracetamol tablets

Marksans Pharma Limited (Reuters: MARK.BO; Bloomberg: MRKS IN; NSE: MARKSANS; BSE: 524404) has announced that its wholly owned subsidiary in UK Relonchem Limited has received Marketing Authorization for the product Ibuprofen and Paracetamol 200 mg/500 mg Film-coated Tablets (Bell's Healthcare Dual Action Pain Relief 200 mg/500 mg Film-coated Tablets).

Shares of Marksans Pharma Limited was last trading in BSE at Rs. 219.65 as compared to the previous close of Rs. 225.65. The total number of shares traded during the day was 62303 in over 1411 trades.

The stock hit an intraday high of Rs. 227.55 and intraday low of 218.15. The net turnover during the day was Rs. 13885950.00.

Source : Equity Bulls

Keywords

MarksansPharma INE750C01026 UK Relonchem MarketingAuthorization Ibuprofen Paracetamol